Structure Based Prediction of Binding Affinity of Human Immunodeficiency Virus-1 Protease Inhibitors

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of chemical information and computer sciences

• Publication date

  1999-09-16

• Fields of study

  Medicine, Chemistry, Computer Science

• Identifiers
  DOI 10.1021/ci990019pPMID 10614027
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.

  2010cited by this paper
• Three-dimensional quantitative structure-activity relationship of interleukin 1-beta converting enzyme inhibitors: A comparative molecular field analysis study.

  1999cited by this paper
• Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design.

  1998cited by this paper
• Design and Synthesis of a Novel Series of Nonpeptidic HIV‐1 Protease Inhibitors*

  1998cited by this paper
• Prediction of drug binding affinities by comparative binding energy analysis.

  1997cited by this paper
• Synthesis and pharmacological evaluation of sulfone substituted HIV protease inhibitors

  1997cited by this paper
• Prediction of Ligand-Receptor Binding Thermodynamics by Free Energy Force Field (FEFF) 3D-QSAR Analysis: Application to a Set of Peptidometic Renin Inhibitors

  1997cited by this paper
• Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.

  1996cited by this paper
• VALIDATE: A New Method for the Receptor-Based Prediction of Binding Affinities of Novel Ligands

  1996cited by this paper
• Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.

  1996cited by this paper
• Fitting an inhibitor into the active site of thermolysin: A molecular dynamics case study

  1996cited by this paper
• Computational methods to predict binding free energy in ligand-receptor complexes.

  1995cited by this paper
• Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors.

  1995cited by this paper
• Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.

  1995cited by this paper
• Relative binding free energies of peptide inhibitors of HIV-1 protease: the influence of the active site protonation state.

  1995cited by this paper
• A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site.

  1995cited by this paper
• A molecular mechanics/grid method for evaluation of ligand–receptor interactions

  1995cited by this paper
• Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.

  1995cited by this paper
• Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure.

  1995cited by this paper
• Regulation of MHC class I transport by the molecular chaperone, calnexin (p88, IP90).

  1994cited by this paper
• Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.

  1994cited by this paper
• Protein structure--based drug design.

  1994cited by this paper
• Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors.

  1994cited by this paper
• Application of the three-dimensional structures of protein target molecules in structure-based drug design.

  1994cited by this paper
• NMR and X-ray Evidence That the HIV Protease Catalytic Aspartyl Groups Are Protonated in the Complex Formed by the Protease and a Non-Peptide Cyclic Urea-Based Inhibitor

  1994cited by this paper
• Prediction of the protonation state of the active site aspartyl residues in HIV-1 protease-inhibitor complexes via molecular dynamics simulation

  1993cited by this paper
• Crystal structures of HIV-1 protease-inhibitor complexes

  1993cited by this paper
• Protein docking algorithms: simulating molecular recognition

  1993cited by this paper
• FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA

  1993cited by this paper
• 3D-QSAR of angiotensin-converting enzyme and thermolysin inhibitors: A comparison of CoMFA models based on deduced and experimentally determined active site geometries

  1993cited by this paper
• On the factors controlling the structural specificity and stereospecificity of the L-lactate dehydrogenase from Bacillus stearothermophilus: effects of Gln102.fwdarw.Arg and Arg171.fwdarw.Trp/Tyr double mutations

  1992cited by this paper
• Partitioning of free energy contributions in the estimation of binding constants : Residual motions and consequences for amide-amide hydrogen bond strengths

  1992cited by this paper
• The cost of conformational order: entropy changes in molecular associations

  1992cited by this paper
• Structure-Based Strategies for Drug Design and Discovery

  1992cited by this paper
• Direct observation by X‐ray analysis of the tetrahedral “intermediate” of aspartic proteinases

  1992cited by this paper
• HIV protease: a novel chemotherapeutic target for AIDS.

  1991cited by this paper
• Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor.

  1991cited by this paper
• Determination of the relative binding free energies of peptide inhibitors to the HIV-1 protease.

  1991cited by this paper
• Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism.

  1991cited by this paper
• Human immunodeficiency virus-1 protease. 1. Initial velocity studies and kinetic characterization of reaction intermediates by 18O isotope exchange.

  1991cited by this paper
• A rapid finite difference algorithm, utilizing successive over‐relaxation to solve the Poisson–Boltzmann equation

  1991cited by this paper
• Catalytic enhancement of human carbonic anhydrase III by replacement of phenylalanine-198 with leucine.

  1991cited by this paper
• Toward the semiquantitative estimation of binding constants guides for peptide peptide binding in aqueous solution

  1991cited by this paper
• Efficient electrocatalytic and stoichiometric oxidative cleavage of DNA by oxoruthenium(IV)

  1991cited by this paper
• Cholinergic activity of acetylenic imidazoles and related compounds.

  1991cited by this paper
• Human immunodeficiency virus protease: A target for aids therapy

  1990cited by this paper
• The P-loop--a common motif in ATP- and GTP-binding proteins.

  1990cited by this paper
• The 3-D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS.

  1990cited by this paper
• Calculation of the total electrostatic energy of a macromolecular system: Solvation energies, binding energies, and conformational analysis

  1988cited by this paper
• Calculating the electrostatic potential of molecules in solution: Method and error assessment

  1988cited by this paper
• Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

  1988cited by this paper
• Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model

  1985cited by this paper
• Quantitative Structure Activity Relationships of Anthracycline Antitumor Activity and Cardiac Toxicity Based Upon Intercalation Calculations

  1981cited by this paper
• On the size of the active site in proteases. I. Papain.

  1967cited by this paper

• Residue-Ligand Interaction Energy (ReLIE) on a Receptor-Dependent 3D-QSAR Analysis of S- and NH-DABOs as Non-Nucleoside Reverse Transcriptase Inhibitors

  2012cites this paper
• Docking Ligands into Flexible and Solvated Macromolecules. 4. Are Popular Scoring Functions Accurate for this Class of Proteins?

  2009cites this paper
• Conformational Analysis of TMC114, a Novel HIV-1 Protease Inhibitor

  2008cites this paper
• Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go

  2008cites this paper
• Consensus Adaptation of Fields for Molecular Comparison (AFMoC) Models Incorporate Ligand and Receptor Conformational Variability into Tailor-made Scoring Functions

  2007cites this paper
• Unique Thermodynamic Response of Tipranavir to Human Immunodeficiency Virus Type 1 Protease Drug Resistance Mutations (cid:1)

  2007cites this paper
• Improving binding mode predictions by docking into protein-specifically adapted potential fields.

  2005cites this paper
• Application of 3D-QSAR techniques in anti-HIV-1 drug design--an overview.

  2005cites this paper
• Modelling of anti‐HSV activity of lactoferricin analogues using amino acid descriptors

  2005cites this paper
• Cyclic Sulfamide HIV-1 Protease Inhibitors : Design, Synthesis and Modelling

  2005cites this paper
• HIV protease inhibition: limited recent progress and advances in understanding current pitfalls.

  2004cites this paper
• Assessing scoring functions for protein-ligand interactions.

  2004cites this paper
• Simulated dynamics and biological macromolecules

  2003cites this paper
• A New Method for Ligand-supported Homology Modelling of Protein Binding Sites: Development and Application to the neurokinin-1 receptor

  2003cites this paper
• Structure-based prediction of free energy changes of binding of PTP1B inhibitors

  2003cites this paper
• Simulated dynamics and biological macromolecules

  2003cites this paper
• Inhibition and substrate recognition – a computational approach applied to HIV protease

  2003cites this paper
• Molecular dynamics simulation characteristics of resveratrol interaction with human estrogen receptor-α: distinct recognition from diethylstilbestrol

  2002cites this paper
• DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein.

  2002cites this paper
• Computational Studies of HIV-1 Protease Inhibitors

  2002cites this paper
• Statistical potentials and scoring functions applied to protein-ligand binding.

  2001cites this paper
• Computational studies of protein-ligand molecular recognition

  2001cites this paper
• Structure Based Prediction of Binding Affinity of Human Immunodeficiency Virus-1 Protease Inhibitors.

  2000cites this paper
• Selectivity analysis of 5-(arylthio)-2,4-diaminoquinazolines as inhibitors of Candida albicans dihydrofolate reductase by molecular dynamics simulations

  2000cites this paper
• Computational and functional analysis of the putative SH2 domain in Janus Kinases.

  2000cites this paper